PMC:7696151 / 37621-37914 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1106","span":{"begin":71,"end":74},"obj":"Chemical"},{"id":"1107","span":{"begin":176,"end":179},"obj":"Chemical"},{"id":"1116","span":{"begin":206,"end":214},"obj":"Disease"}],"attributes":[{"id":"A1106","pred":"tao:has_database_id","subj":"1106","obj":"MESH:D006886"},{"id":"A1107","pred":"tao:has_database_id","subj":"1107","obj":"MESH:D006886"},{"id":"A1116","pred":"tao:has_database_id","subj":"1116","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Food and Drug Administration (FDA) had initially authorized the use of HCQ in case of emergency [61], in June 2020, the FDA revoked this authorization [62] since the potential HCQ effectiveness in treating COVID-19 was overtaken by severe cardiac adverse events and other serious side effects."}

{"project":"LitCovid-sentences","denotations":[{"id":"T248","span":{"begin":0,"end":293},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Food and Drug Administration (FDA) had initially authorized the use of HCQ in case of emergency [61], in June 2020, the FDA revoked this authorization [62] since the potential HCQ effectiveness in treating COVID-19 was overtaken by severe cardiac adverse events and other serious side effects."}